Bring those fins!!!

Looks like (based on volume) everyone is waiting to see.

VANCOUVER, BC, July 12, 2021 /CNW/ - Village Farms International, Inc. (the "Company" or "Village Farms") (TSX: VFF) (NASDAQ: VFF) today announced that it has filed a universal shelf registration statement on Form S-3 (the "New Registration Statement") with the United States Securities and Exchange Commission (the "SEC"), for an unlimited amount of securities that may be offered from time to time in the future, replacing the shelf registration statement on Form S-3 filed with the SEC in April 2020. Village Farms has become a "well-known seasoned issuer" ("WKSI") under SEC rules and is filing the New Registration Statement to take advantage of certain benefits only available to WKSIs.

The filing of the New Registration Statement will provide Village Farms flexibility to issue securities in one or more future offerings, including when needed to pursue strategic opportunities. The specific terms of any such offering will be described in detail in a prospectus supplement filed at the time of such offering(s). At this time, Village Farms does not have any immediate plans to offer securities under the New Registration Statement

This press release is not an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offering of the securities covered under the New Registration Statement will be made solely by means of the prospectus included in the New Registration Statement and an accompanying prospectus supplement relating to that offering to be filed with the SEC.

A copy of the New Registration Statement is available on www.sec.gov and on SEDAR at www.sedar.com.

Support at .0326 US (Which I dont think it will fall through because of the current volume) tells me to accumulate between .034 to .0326. (if it gets to or below .034)

Which is exactly what I will do. Of course all of this is JMHO.

It it falls through support, I feel comfortable enough with this company to average it down.

GLTA

Namaste will have a clear path (to either the moon or the basement) based on the next 2 Q's. I personally think they are going to shock the sector.

I nibbled on DMAN yesterday at 34 and that is proving nice.

GL

I would be totally ok with that

Took a nibble of 30,000 shares today

I dont deal in absolutes like "Always" and "Never" and "No Point"

I encourage people to do their own due diligence as your comments are misleading IMO (if you dont have a short interest)

Village is one of the only ones doing it correctly in the sector and has hedged their risk with the produce portion of the business (which prices are rising dramatically for produce) and that will be even more evident as the year unfolds. IMO

I am a buyer at these levels. Are you?

***insert a convoluted "answer" that doesn't say "yes" or "no" here***

um. ok. hmmmmmmmmmmm eeeeeeee booooooooo OK.

Are you a buyer at these levels or just looking to cover?

Well.........yep..............cool. Up and Down. Bing.......boing.

"There's no point in trying to hold on"----Silly

left----right-----oh ok.

Place a trend line and a circle here

OR

Buy low and sell high

VFF

Shaping up nicely

The wait will be worth it. IMO

Wed, June 2, 2021, 7:26 AM
Canadian meme stock

Reddit users have crossed the border in the past. Last year they successfully targeted BlackBerry stock. Now, another Canadian company has significant short interest and a meme-worthy business model.

Village Farms International (TSX:VFF)(NASDAQ:VFF) is the ideal target for a Reddit-driven short squeeze. The company’s short interest is 21% at the moment, which is just as high as AMC stock. That means one in every five shares has been bet against by professional investors.

The fact that this is a cannabis company makes it even more exciting. Cannabis stocks have been a prime focus for retail investors ever since legalization in Canada. Now, in 2021, the U.S. government is moving to legalize the substance. That means that Village Farms, which has operations in the U.S., actually has a decent runway for growth.

Many analysts believe the stock is undervalued. But the fact that it is also heavily shorted means it could be a potential target for a short squeeze or a worthy meme stock. A small, speculative position in this tiny Canadian company may not be such a bad idea.

Bottom line

Meme stocks are usually interesting companies with heavy short interest. AMC stock has roughly 20% short interest, which is why Reddit users have been able to push it so high. Canada’s most shorted company, Village Farms International, could be a similar target.

AMC Entertainment Holdings (NYSE:AMC) stock has been on an epic run this week. The share price is up 266% over the past two weeks and up 1,732% since the start of the year. That performance is better than most other meme stocks and is even better than most major cryptocurrencies.

Why invest in a bleeding-edge new digital technology when you can simply bet on a rebound in cinemas? However, investors aren’t just betting on the revival of entertainment here. They’re also deploying a coordinated short-squeeze strategy that has worked so well over the course of the pandemic.

If you’re trying to understand why AMC stock is on such a tear and which stock could be next, here’s a deep dive.

AMC stock action

This surge in AMC stock is anything but organic. Last year, Reddit users on the WallStreetBets forum discovered that the stock was heavily shorted. This means hedge funds and institutional investors were betting against the stock. Reddit users could buy the stock to push it up and compel these big investors to close their trade by purchasing the stock and pushing the price even higher.

This sophisticated strategy is known as a short squeeze; it was traditionally deployed by professional investors. This year, retail investors have been able to pull this strategy off by coordinating attacks.

AMC stock has been their most successful target. Despite the squeeze over the past year, 21%, or roughly one in five shares of AMC are still being shorted. That means there’s more room to run.

This week, the company raised US$230.5 million (C$277 million) from hedge fund Mudrick Capital. The money is being used to acquire new companies and pay down debt. It seems the short squeeze has been so successful that it’s actually saving this company from bankruptcy.

Something is up. Bring the news

Wish it would do that off of $2 instead of trips

SQUEEEEEEEEEEEEEEEEZE!!!!!!!!!!!

Thanks Mike!

Agreed. I am buying through out the summer which tends to be historically a bearish period for MJ anyway.

Down 27% on that report? Nope. This overreaction is going to make me a ton of money.

How about you?

This overreaction is awesome! #loading

Just stay in this range until noon tomorrow

Yepper

Emerald Health Therapeutics (OTCQX:EMHTF): FY net loss of C$43.54M
Revenue of C$11.74M (-42.2% Y/Y)

OUCH

https://norml.org/blog/2021/04/19/us-house-passes-bill-to-normalize-adult-use-cannabis-commerce/

April 15, 2021 01:02 PM ET (BZ Newswire) -- Cannabis
Multi-country medical and recreational cannabis operator IM Cannabis (CSE:IMCC) (NASDAQ:IMCC) is gearing up to expand its product offering in the German market this year with a range of specially formulated high-THC, balanced-THC and CBD oil extracts.
The company announced its German subsidiary, Adjupharm GmbH, signed a two-year supply agreement with MediPharm Labs (OTC:MEDIF) for the production and delivery of IMC-branded, specially formulated extracts. The products will be distributed by Adjupharm and its network to more than 6,000 pharmacies across Germany. 
“The agreement with MediPharm is part of our multipronged approach to growing IMC’s business in key international markets not only through M&As," Oren Shuster, CEO of IMC, told Benzinga, "but also by the leveraging strong business relationships to enable the introduction and expansion of premium product portfolio to cater to the needs of patients and physicians. As demand for premium medical cannabis extracts grows in Germany, it provides an excellent opportunity for IMC to deploy this strategy.”
The agreement with MediPharm Labs comes on the heels of another supply agreement IMC announced earlier this week with Canadian-based Northern Green Canada to supply IMC-branded medical cannabis to the German market as well.

April 8, 2021 01:09 PM ET (BZ Newswire) -- Cannabis
Skye Bioscience Inc. was a sponsor at the Benzinga Cannabis Capital Conference on February 25-26, 2021. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.
From the first research of tetrahydrocannabinol(THC) in 1964 by Raphael Mechoulam to the recent findings of the hundreds of cannabinoids that can alleviate symptoms of a plethora of illnesses and diseases, we now know cannabis is more than just weed and about getting high. 
Skye Bioscience Inc. (OTCQB:SKYE), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet needs recently presented at the Benzinga Cannabis Capital Conference its approach to treating Glaucoma through unlocking the pharmaceutical value of THC. 
Here’s what you need to know.

Glaucoma — An Important Unmet Need
According to a report on vision by the World Health Organization (WHO), at least 2.2 billion people suffer from vision impairment or blindness, of which over 1 billion cases could have been prevented or have yet to be addressed. 
Glaucoma is a disease that leads to the progressive damage of retinal ganglion cells, which make up the optic nerve, and without intervention will gradually lead to irreversible blindness. In most cases, there is no pain and the loss of vision occurs gradually from peripheral to central and unfortunately, in many instances, people with glaucoma do not even realize it until they start experiencing some degree of permanent loss of vision
In fact, over 3 million Americans have glaucoma but only half of those know they have it. In addition, this disease accounts for over 10 million visits to physicians per year in the United States, and the estimation of suspected cases are close to 60 million worldwide.
 of irreversible blindness and it ranks among the main reasons for the usage of medical marijuana. 

A Light In The Horizon — Relevance Of THC To Glaucoma
The primary aim for currently used therapies is to lower intraocular pressure (IOP) to slow the progression. Yet, many patients are unresponsive or develop tolerance to medication leaving notable unmet needs, resulting in more than 50% of patients requiring 2 or more drugs which can increase side effects and reduce compliance. The market has lacked significant innovation, thus presenting an opportunity and need for new classes of therapy. 
Cannabinoids have a great impact on the endocannabinoid system (ECS) — eyes are rich with cannabinoid receptors, specifically in tissues involved in managing fluid production and drainage as well as cells responsible for vision.
Multiple independent studies have demonstrated THC’s ability to lower IOP. In fact, the first report that smoking cannabis lowers IOP appeared in the early 1970s, and since then multiple human studies have validated THC’s ability to lower IOP. However there have been challenges creating a viable therapeutic with systemic delivery of THC for glaucoma because of poor,unpredictable pharmacokinetics and potential side effects.

Unlocking the therapeutic value of THC
Skye’s approach is designed to provide advantages over currently approved drugs and natural cannabinoids to treat glaucoma. Skye’s synthetic THC prodrug called THCVHS is engineered to enhance its local delivery — avoiding systemic side effects and enhancing bioavailability in the eye.
In an animal study comparing latanoprost, the glaucoma standard-of-care, THCVHS was superior in a key outcome of lowering IOP. THCVHS may also provide unique neuroprotection to prevent another key cause of vision loss — optical nerve cell death. 
Skye is working toward its Phase 1 study planned for H2 2021, which will primarily assess safety and tolerability but will also measure IOP in both healthy subjects as well as a smaller subset of patients with elevated IOP. The nature of glaucoma allows this study to be relatively short and low cost.

Corporate highlights 
Skye Bioscience, previously Emerald Biosciences, introduced a series of incoming results from pre-clinical and clinical-enabling studies. Should the results prove positive, they would pave the way for an Investigational New Drug (IND) application into what is a potentially $10 billion drug market.
Some of the company’s highlights include:


Demonstrated greater IOP lowering than market-leading glaucoma therapeutics 

Potential neuroprotection capabilities would be a game-changer

Key preclinical data (IOP/neuroprotection) in Q221

First clinical trial: fast; low-cost; will include assessment of intraocular pressure 

Many glaucoma licensing deals have been completed in phase 2 or earlier 

$40 million market cap

$350 million outstanding common shares

$472.7 million fully diluted shares
 

Copyright © 2021 Benzinga (BZ Newswire, http://www.benzinga.com/licensing). Benzinga does not provide investmentadvice. All rights reserved. Write to editorial@benzinga.com with any questions about this content. Subscribe to Benzinga Pro (http://pro.benzinga.com).

250k on the ask. Shorts has us by the ding ding but thats ok. I like where we are going now.

Thanks for the .232sssssssssss

NXTTF

I think you are close. I have a hard time believing they would say 8m if they werent confident of surpassing that.

I have some powder on the sidelines if the fins show what I would like to see. I also said that I wouldnt spend another penny here until I saw proff of heading in the right direction.

IMO- I think the team has positioned themselves to under promise and over deliver. I think the results will be stellar.

NXTTF

https://www.fool.com/investing/2021/03/25/2-pot-stocks-that-can-double-your-1400-stimulus-pa/

Short Attack

Positions themselves to sell to states as the state legalizes. #brilliant

Dead money

OH MY!

Sold half at .525

Trailing stop set on the rest.

GLTA

I have begun buying here

Ton of volume the last hour or so

Trying to hold her back but she wants to go

Everybody load up on those 16's??

Lets gooooooooooooooo

VFF

IIROC Trading Resumption - N
Feb 12, 2021

VANCOUVER, BC, Feb. 12, 2021 /CNW/ - Trading resumes in:

Company: Namaste Technologies Inc.

TSX-Venture Symbol: N

All Issues: Yes

Resumption (ET): 1:30 PM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions


For further information: For further information about IIROC's trading halt policy, please see Trading Halts & Timely Disclosure (http://www.iiroc.ca/industry/marketmonitoringanalysis/Pages/Trading-Halts-Timely-Disclosure.aspx) at www.iiroc.ca under the Halts & Resumptions tab. Please note that IIROC staff cannot provide any information about a specific halt beyond what is contained in this halt notice. For general information about IIROC, contact IIROC's Complaints & Inquiries team at inquiries@iiroc.ca or 1-877-442-4322 (Option 2). For company-related enquiries, contact the company directly.

We expect to have CannMart Labs manufactured products in the market by the end of Q2 2021.

LICENSE!!!!!

TORONTO , Feb. 12, 2021 (GLOBE NEWSWIRE) -- Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) a marketplace platform for cannabis and wellness products, is pleased to announce that its wholly owned subsidiary CannMart Labs Inc. (“ CannMart Labs ”) has received a standard processing licence from Health Canada (the “Standard Processing Licence”). The Company will now focus on the next step in the process, which is commissioning the equipment, a process which will commence immediately. The Company will leverage its existing sales licence through CannMart Inc. to bring our recreational products to provinces in Canada where Namaste already has a distribution network in place. We expect to have CannMart Labs manufactured products in the market by the end of Q2 2021.
Highlights of CannMart Labs :
CannMart Labs facility in Ontario is established for BHO extraction using leading extraction technology, making it one of only a few facilities in Canada with such capabilities.
Set to produce in-house branded Cannabis 2.0 products for medical channel customers at CannMart.com and recreational customers across Canada through sister company CannMart's network of provincial sales partners.
Cannabis 2.0 products initially planned include shatter, live resin, badder, wax and others with capabilities to expand future distillate product offerings to vape cartridges, gel capsules, tinctures and edibles. In addition, we will be looking to add solventless products such as rosin to our portfolio in the near future.
Namaste owns 100% of the CannMart Labs facility, which is located in Etobicoke, Ontario , a purpose-built oil extraction facility which incorporates a leading extraction technology facility designed to meet EU Good Manufacturing Practice (EU-GMP) certification requirements. We will look at selling our manufactured products to other licensed producers and other sales channels as they become available.
“This is a major catalyst for Namaste to generate material revenue through the sale of new and exciting cannabis products and by offering contract manufacturing services to our partners,” said Meni Morim , CEO of Namaste. “The team has selected and installed state-of-the-art extraction equipment and technology in its facility, which will be able to produce an array of cannabis products including shatter and live resin, as well as future distillate products such as vape cartridges, gel capsules, tinctures and edibles. We look forward to producing our in house branded Cannabis 2.0 products, including “ROILTY” for our medical channel customers at CannMart.com and recreational consumers across Canada through our network of provincial sales partners.”
About Namaste Technologies Inc.
Headquartered in Toronto, Canada , Namaste Technologies is a marketplace platform for cannabis and wellness products. At CannMart.com, the Company provides Canadian medical customers with a diverse selection of hand-picked products from a multitude of federally licensed cultivators and will provide US customers with access to smoking accessories and hemp-derived CBD. The Company also distributes licensed and in-house branded cannabis and cannabis derived products in Canada through a number of provincial government control boards and retailing bodies and facilitates licensed cannabis retailer sales online in Saskatchewan . Namaste’s global technology and continuous innovation address local needs in a burgeoning cannabis industry requiring smart solutions.
Information on the Company and its many products can be accessed through the links below:
NamasteTechnologies.com
NamasteMD.com
Cannmart.com
For more information please contact: Namaste Technologies Inc. Meni Morim , CEO Edward Miller , VP Investor Relations Ph: 647-362-0390 Email: ir@namastetechnologies.com
FORWARD-LOOKING INFORMATION – This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as “may”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen. The forward-looking information contained herein, including, without limitation, statements related to the qualification of CannMart Labs equipment, CannMart Labs’ ability to bring products, including planned Cannabis 2.0 to market by the end of Q2, 2021 and the expectation to generate material revenue therefrom and from contract manufacturing services offered to third parties, the possible future expansion of distillate products to include vape cartridges and other products is made as of the date of this press release and is based on assumptions management believed to be reasonable at the time, including, without limitation, its ability to qualify the equipment under the Standard Processing Licence in a timely manner, the level of interest by third parties to seek contract manufacturing services from Namaste, Namaste’s standing in the online marketplace for cannabis products, Namaste's beliefs regarding the expected demand for cannabis products, including Cannabis 2.0 products, and the expected growth of that market, results of operations, operational matters, historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation: the inability of the Company to qualify the equipment in a timely manner, the failure of the CannMart Labs facility to be operational as expected, the generation of material revenue not being as anticipated, regulatory risk, risks relating to the Company’s ability to execute its business strategy and the benefits realizable therefrom and risks specifically related to the Company’s operations. Additional risk factors can also be found in the Company’s current MD&A and annual information form, both of which have been filed under the Company’s SEDAR profile at www.sedar.com. Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange ) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

We are halted folks!


IIROC Trading Halt - N
Feb 12, 2021

VANCOUVER, BC, Feb. 12, 2021 /CNW/ - The following issues have been halted by IIROC:

Company: Namaste Technologies Inc.

TSX-Venture Symbol: N

All Issues: Yes

Reason: At the Request of the Company Pending News

Halt Time (ET): 12:24 PM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions


For further information: For further information about IIROC's trading halt policy, please see Trading Halts & Timely Disclosure (http://www.iiroc.ca/industry/marketmonitoringanalysis/Pages/Trading-Halts-Timely-Disclosure.aspx) at www.iiroc.ca under the Halts & Resumptions tab. Please note that IIROC staff cannot provide any information about a specific halt beyond what is contained in this halt notice. For general information about IIROC, contact IIROC's Complaints & Inquiries team at inquiries@iiroc.ca or 1-877-442-4322 (Option 2). For company-related enquiries, contact the company directly.

Come to papa